Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could ozempic stop pancreatitis from coming back?

NCT ID NCT07617155

Prevention Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether semaglutide (Ozempic/Wegovy) can prevent repeat episodes of acute pancreatitis caused by very high triglycerides. About 396 adults who recently had such an attack will receive either semaglutide injections or a placebo for 18 months, alongside standard care. Researchers will track how many have another pancreatitis episode and whether their triglyceride levels improve.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Semaglutide (Ozempic, Wegovy)
What this could lead to
If it works, this could offer a new way to prevent repeat episodes of severe pancreatitis in people with very high triglycerides.
What could go wrong
This is a Phase 4 trial that hasn't started yet. The drug may not reduce pancreatitis risk, and side effects like nausea or rare gallbladder issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 396 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Age ≥ 18 years old * Previous diagnosis of index HTG-AP (defined as AP with serum TG \>1000 mg/dL or a serum TG level of 500-1000 mg/dL accompanied by chylous serum)36-38 * Having HTG as the exclusive cause of AP * Time from discharge of index HTG-AP to recruitment between 4 weeks to 3 months, without AP-related symptoms between discharge and recruitment * Expression of the willingness to comply with lifestyle modification during the study period. * Clinically stable at the time of inclusion * The ability to understand the trial and completing it, as evaluated by the investigators. * Patients who may get pregnant should ensure using contraceptives for 20 months after inclusion Exclusion Criteria * History of malignancy in past 5 years * History of hypothyroidism, nephrotic syndrome, Cushing's syndrome or AIDS * History of chronic pancreatitis or pancreatic neoplasm * History of severe cardiovascular and pulmonary diseases, such as heart failure, coronary heart disease and chronic obstructive pulmonary disease. * Severe renal deficiency (glomerular filtration rate \< 30 ml/min) * Severe hepatic deficiency (Child-Pugh Class B or C) * Previous pancreatic surgery * Recurrent AP due to pancreatic diverticulum * Recurrent AP due to known genetic mutations (eg. CFTR) * Personal or family history of medullary thyroid carcinoma (MTC) * Current or prior diagnosis or suspected diagnosis of multiple endocrine neoplasia type 2 (MEN2) * Serious hypersensitivity reaction to semaglutide or any of the excipients in the investigational drug or placebo * Pregnancy * Breast-feeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertriglyceridemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic pancreatitis hypertriglyceridemia pancreatitis recurrent acute pancreatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertriglyceridemia Hypertriglyceridemia induced acute pancreatitis Pancreatitis relapsing Recurrent acute pancreatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.